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CHAPTER 1: INTRODUCTION
Nutrigenomics is the scientific study of the specific way in which specific genes interact
with bioactive food components and affect the genome without altering DNA structure [1].
Nutrigenomics allows nutritionists and microbiologists to elucidate the mechanisms by which
nutrients have an impact on the genome [1]. It is important to investigate how several cellular
processes in the human body can be modified by foods that interact with gene expression.
Nutrition affects brain structure, function and development throughout the life cycle and can
have profound implication on cognition, mental health and degenerative diseases [2].
Neurodegenerative diseases affect more than 30 million people throughout the world causing
mental disability and death. There are essential and nonessential nutrients that are known to have
an impact on metabolism, hormonal balance, energy balance, cell cycle signaling and regulation,
apoptosis and angiogenesis [3]. Dietary folate has become an interesting food component to
study in the rising field of nutrigenomics. Folate deficiency has been studied extensively due to
its association with chronic diseases, such as Alzheimer’s disease, cancer and cardiovascular
disease [4].
A. Folate
Folate is an essential water soluble vitamin that plays a role in several mechanisms and
pathways in relevance to etiologies of birth defects and chronic diseases. Folate or folic acid is
found to be available in most plant based foods, however it is often found to be under-consumed
in the diets of individuals that eat low amounts of fruits and vegetables [5]. Folate is found in our
diets as bioactive forms of fundamental B vitamins [6]. Folate is naturally available in foods as
“pterolypolyglutamates”, and it is used in vitamin supplements and fortified food products in the
form of “monoglutamate folic acid” [6]. Folic acid is the most stable and fully oxidized form of
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folate and has a greater bioavailability, therefore it is the form used in fortified foods [7]. Folic
acid acts as a coenzyme in the metabolism of amino acids and nucleic acids and plays an integral
role in many cellular pathways, DNA and RNA synthesis, cellular replication, intracellular
signaling and regulation of cell division [6, 7]. All of these processes are implicated in fetal and
placental growth and development; therefore it is crucial to maintain the levels of this vitamin
throughout the early stages of development and growth [6, 8]. For this reason, in 1998 the United
States and Canada mandated folic acid fortification in staple food items such as most grains and
cereal products [8].
B. Neural Tube Defects (NTDs)
Poor folate status in women of child-bearing age and pregnant women is known to cause
NTDs, miscarriages, and premature births [8]. Neural tube defects involve the incomplete
development of the embryonic structure that becomes the brain and/ or spinal cord; there are two
common types of NTDs: spina bifida and anencephaly [9]. This defect occurs when the brain and
spinal cord are left susceptible due to the due to the failure of the neural tubes closing [10].
Anencephaly is the most severe and spina bifida can cause a range of morbidities; which
includes the paralysis of the lower limbs and urinary and fecal incontinence [11].
The exact mechanism by which folate reduces the risk for NTDs still remains as a part of
active research [11].The British Medical Research Council conducted a randomized control trial
to determine the effectiveness of folic acid supplementation in the prevention of recurrence of
NTDs; it was observed that by taking 4000 micrograms of folic acid the risk of NTD recurrence
was reduced by 70% [11]. By 1992 the U. S Public Health Service recommended that women of
child bearing age should consume 400 µg of folic acid daily through supplementation and diet to
prevent NTDs [11]. However encouraging women to consume 400 µg of folic acid through
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supplementation has limitations due to the fact that almost more than 50% of pregnancies in the
United States are unplanned [11]. Therefore in 1998 a mandatory folic acid fortification was
implemented to provide 140µg per 100g to all enriched cereal grain products and had been
estimated to provide 100-200µg of folic acid to women of childbearing age [11]. A significant
decrease in the prevalence of NTDs has been observed across the United States and many other
countries since the mandatory implementation in 1998 of folic acid fortification [11].
C. Potential Adverse Effects of Folate Fortification
There are always concerns regarding adverse effect consequences to any type of public
health intervention as it becomes critical to monitor any and all fortification programs to address
any type of emerging concerns. With folic acid fortification, the main concerns that have been
monitored are: 1.) Masking of B12 Deficiency Anemia, 2.) Cancer and Epigenetic Changes and
3.) Unmetabolized Folic Acid.
1.) Masking of B12 Deficiency Anemia
Early case reports suggested that the consumption of folic acid in amounts <5000µg daily could
possibly mask Vitamin B12 deficiency by preventing the development of anemia. If masked and
not diagnosed at an early stage, this masking could allow for the progression of Vitamin B12
deficiency related neuropathies. However several studies done prior to and after fortification,
suggest that there is very little evidence of neuropathies [11].
2.) Cancer and Epigenetic Changes
Studies indicate that a diet high in the consumption of folate through fruits and vegetables can
reduce the risk of certain types of cancers. As a result of this assumption studies are being
conducted to elucidate the mechanism by which folate impacts epigenetic patterns. Folate plays a
key role in two important epigenetic modifications-- DNA synthesis and methylation. Since
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folate is involved as a one carbon methyl group in DNA methylation, studies are focusing on
how it can positively or negatively affect any disease, especially tumorgenesis [11]. Some
studies hypothesize that an early and adequate exposure to folic acid may prevent the
development of tumor cells through the provision of enough methyl groups during DNA
methylation. However other studies show that a higher intake of folic acid may promote the
growth of pre-existing tumors [11]. Nonetheless, further studies must be conducted to determine
the way in which folic acid has an impact on epigenetic patterns through a mechanistic approach.
3.) Unmetaoblized Folic Acid
An excess intake of folic acid can result from an increased consumption of fortified supplements
and foods (such as cereal grain products). If the body exceeds the capacity to metabolize folic
acid, the folic acid will be found circulating in the blood [12]. Thus far it has been hypothesized
that unmetablized folic acid is related to cognitive decline and impairment among seniors [12,
13].
D. Folate One-Carbon Metabolism
As stated earlier, folic acid plays an integral role in many cellular pathways, including
DNA and RNA synthesis, cellular replication, intracellular signaling and regulation of cell
division [6, 7]. Folate is the central focus of the one-carbon metabolism pathway and plays in
integral in the regulation of the pathway. The one- carbon metabolism pathway is displayed in
the figure below:
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Figure 1-1: Folate Metabolism [14]
A polyglutamyl form of the tetrahydrofolate (THF) group is the main factor involved in onecarbon metabolism; this acceptor molecule is 5-methylenetetrahydrofolate (5-methyl THF) [15].
The most crucial step in the pathway to provide the 3 carbon serine (major carbon source) is the
conversion of THF to 5, 10-methylene THF [15]. Serine uses this one-carbon unit to form 5, 10methylene-THF and glycine from THF via serine hydroxymethyltransferase (SHMT). The
enzyme responsible for the irreversible conversion of 5, 10 methylene-THF to 5-methyl THF is
methylenehydrofolate reductase (MTHFR). The N-5 methyl group of 5-methyl THF can only be
used metabolically for transfer to homocysteine, which results in the regeneration of methionine;
in the methionine synthase reaction, demethylation of the 5-methyl THF occurs and this methyl
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group is sequentially transferred to the vitamin B-12 coenzyme before homocysteine, thus
forming methionine [15]. The produced methionine is then broken down to the methyl donor
group: s-adenosylmethionine (SAM), as demethylation continues, s-adenosyl-L-homocysteine
(SAH) is converted into homocysteine.

Furthermore, the conversion of deoxyuridine

monophosphate (dUMP) to thymidine monophosphate (dTMP) via the enzyme thymidylate
synthase (TS) occurs during the pyrimidine biosynthesis pathway [16]. The most important
functions involved in folate metabolism are: the transfer of one-carbon in the methionine cycle,
the synthesis of purines (adenine and guanine) and the DNA methylation reactions. These
reactions are a required to maintain the integrity of genetic material and sustain DNA
proliferation. However this pathway can be altered when folate status is compromised and can
lead to harmful epigenetic changes.
When folate status is compromised, several reactions in one-carbon metabolism are
affected and can lead to negative consequences. The regulation of this pathway is tightly
controlled by the synthesis of methyl groups and other one-carbon units; folate and relevant
coenzymes are categorized between mitochondria and cytosol [16]. The inhibition of MTHFR
by SAM can suppress the production of 5-methyl-THF; therefore the presence of excess methyl
groups can further the de novo biosynthesis of methyl groups [16]. Inadequate folate status
during severe deficiency can impair one-carbon metabolism, however since 5-methyl and 5formyl-THF play the role of SHMT inhibitors marginal deficiency may only effect the carbon
flux marginally due to their effects being diminished [16]. In a low folate status condition, the
regulation of SAM would be disrupted, the concentration of SAH would increase due to the
failure of methyl group synthesis and homocysteine re-methylation [17].
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E. Neurodegenerative Diseases
As stated earlier, inadequate folate intake during pregnancy increases the risk of
abnormalities of the fetus. Folate deficiency has also been associated with neurodegenerative
conditions, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral
sclerosis (ALS) and stroke in the elderly [18]. Folate deficiency alters SAM- dependent histone
methylation. Compromised histone methylation has been associated with impaired learning and
memory, intellectual disability, autism, and neurodegeneration [18]. A rise in homocysteine
serum concentration and a decreased SAM/SAH ratio can impair cerebral function and interfere
with cognitive function leading to dementia and Alzheimer’s disease [19].
Alzheimer’s is a progressive neurodegenerative disease associated with brain shrinkage
and loss of neurons, leading to loss of brain function. Alzheimer’s is characterized by loss of
memory and language, irritability, confusion, dementia, aggressive moods and loss of
physiological conditions [20]. A compromise in one-carbon metabolism can accompany and may
be the possible cause of neurodegeneration of Alzheimer’s Diseases [18]. In individuals with
Alzheimer’s disease, SAH levels are elevated and they competitively inhibit SAM-dependent
reactions, which in turn reduces methylation reactions [18].
Elevated homocysteine levels have also been reported to cause cognitive decline and
depression in patients with Parkinson’s disease [21]. Parkinson’s disease is a progressive nervous
system disease that impairs movement. Homocysteine has the capability to exert neurotoxic
effects which can decrease the movement and function on neural cells; elevated levels of
homocysteine may increase the risk of Parkinson’s disease by having a direct effect on
dopaminergic neurons [21].
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Huntington’s disease (HD) is an inherited autosomal dominant neurodegenerative disease
which does not have an effective treatment or cure. It is characterized by neuron loss, psychiatric
disturbances and dementia [22]. Higher plasma levels of homocysteine have been observed in
patients with HD. Due to the regulatory effects of folic acid on homocysteine metabolism, it has
been suggested that folic acid supplementation maybe helpful in HD [23]. However it has not
yet been established that folic acid supplementation can provide any type of therapeutic effects in
patients with HD.
The adverse effects of folate deficiency and elevated homocysteine levels on the
developing central nervous system suggests that the alteration in one-carbon metabolism and
homocysteine levels may play a role in the pathogenesis of age-related neurodegenerative
diseases [24]. Homocysteine can damage, kill and promote the degeneration of neurons by
impairing DNA repair; it has been suggested that elevated levels of homocysteine may increase
the vulnerability of the CNS to neurodegenerative diseases [24].
F. mTOR Pathway
The mammalian target of rapamycin (mTOR) pathway responds to several environmental
cues and integrates these signals to regulate cellular growth and homeostasis [25]. The mTOR
pathway impacts most major cellular functions due to its regulation of basic cell functions of
growth and proliferation [25]. The deregulation and/or alteration of this pathway occur in many
human diseases, such as cancer, obesity type 2 diabetes and neurodegenerative diseases. mTOR
is a serine/threonine protein kinase that belongs to the phosphoinositide 3-kinase (PI3K) family;
it interacts with proteins to form two specific multi- complexes mTORC1 and mTORC2 [25].
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Figure 1-2: Overview of mTORC1 and mTORC2 [25]
The mTORC1 complex integrates inputs from intra and extra cellular environmental cues (stress,
amino acids, energy status, and growth factors) to regulate processes of protein and lipid
synthesis, energy metabolism, development and autophagy mainly [25]. The mTORC2 responds
to growth factor signals to regulate cell survival and migration [26].

Both of the mTOR

complexes have different sensitivities to rapamycin, along with different signaling of upstream
input and downstream output [25]. The mTOR signaling network/pathway can be seen in the
figure below:
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Figure 1-3: mTOR signaling Network [28]
The mTOR pathway responds to several environmental cues to impact most major
cellular functions; basic cell functions of growth and proliferation. mTORC1 is activated by the
PI3K and AKT pathways and mTORC2 is activated via signaling from the RAS and RAF
(protein kinases) pathways [26]. As seen in the diagram: mTORC1 is composed of mTOR,
PRAS40, mLST8 and raptor (rapamycin-sensitive); mTORC2 is composed of mTOR, PRR5/5L,
mSIN1, mLST8 and rictor (rapamycin-insensitive) [28]. TSC1/2 functions as a GTP-ase
activating protein for the Ras homolog enriched in the brain- Rheb; it acts as a key upstream
regulator of mTORC1 to activate kinase activity and it transmits signals that affect mTORC1
(such as insulin and insulin-like growth factors) [28].
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mTORC1 directly targets two translational initiation factors, 4E-BP1 and S6K1 by
phosphorylating them to promote protein synthesis. The phosphorylation of S6K1 mediates the
phosphorylation of and activates the 40S ribosomal protein S6 which in turn enhances translation
of mRNA [29]. The phosphorylation of 4E-BP1 prevents it from binding to eIF4E (cap-binding
protein), leading it to form the eIF4E complex required to mediate cap dependent translation [25,
29].

Growth factors activate mTORC1 indirectly by suppressing TSC1/2 function through

phosphorylation of TSC2 by PI3K/AKT/mTOR pathway; AKT signals phosphorylates and
causes the dissociation from raptor [25, 30].
By contrast the phosphorylation of TSC2 by AMPK due to low energy levels results in
the activation of TSC1/2 thus inhibiting mTORC1 signaling and stimulating autophagy [25].
AMPK is a protein kinase which senses intracellular energy and becomes activated as a response
to low nutrient availability and ATP depletion. REDD 1 is an upstream repressor of mTORC1
and is induced by stress, hypoxia, serum and nutrient deprivation. Although still unclear, it has
been hypothesized that REDD 1 acts to promote the GAP activity of TSC2 toward Rheb
resulting in the accumulation of Rheb-GDP and subsequent repression of mTORC1 signaling
[26].
mTORC2 activates AKT via phosphorylation of the Ser473 form of AKT to indirectly
regulate further activation of AKT [31]. This activation of AKT via mTORC2 signals positive
feedback and could thereby indirectly activate mTORC1 [25, 31, 32]. Inositol polyphosphate
multikinase (IPMK) is kinase that acts as a physiologic mTOR cofactor; it regulates nutrient
amino acid signaling to mTORC1 [33]. IPMK uses its terminal amino acid sequence to stabilize
the binding of raptor to mTOR in the mTORC1 complex [33].
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G.mTOR and Neurodegenerative Diseases
Neurodegeneration is a condition in which the neurons of the brain lose structure and
function, eventually leading to cell death. Alzheimer’s, Parkinson’s and Huntington’s disease are
characterized by the accumulation of misfolded/toxic proteins and related neuronal death. As the
mTOR pathway is involved in several pathways of programmed cell death (autophagy, apoptosis
and necroptosis) it is implicated to be involved in the pathophysiology of neurodegenerative
diseases [34]. The mTOR signaling pathway plays in important role memory formation, fear, and
loss of cognition; it may be required in the hippocampus for synaptic plasticity and memory
formation [35]. Disruption of mTOR signaling can lead to the prevention of long-term
potentiation and memory retention [35].
mTOR activation has been considered as a contributor to the progression of AD however
the level of mTOR activity that is beneficial or detrimental in this condition has not been
determined yet [35]. In mice, the survival of newborn neurons and dendritic density have been
compromised by Beta-Amyloid (Aβ) due to the loss of AKT, mTOR, and p70S6K activity [36].
mTOR has been shown necessary for the formation of long-term memory in the amygdala; loss
of mTOR function can impair memory consolidation [36]. Studies have shown that the activation
of p70S6K has been associated with formation of hyper-phosphorylated tau and neurofibrillary
accumulation. Aβ can be toxic to cells in brains of patients with AD, it can phosphorylate and
activate mTOR and p70S6K in neuroblastoma cells and lymphocytes [35]. In murine models it
has been found that the up-regulation of mTOR activity has been associated with long-term
potentiation and synaptic plasticity [37]. Retinoblastoma tumor suppressor (RB1) inducible
Coiled-Coil 1 (RB1CC1) is necessary for neurite growth maintenance of mTOR signaling. If
there is an insufficiency of RB1CC1 expression, it can result in mTOR activity inhibition, and
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thereby cause neuronal atrophy in patients with AD [37, 38]. Overall, there is growing evidence
demonstrating that the Aβ exerts its toxicity via the mTOR pathway, further supporting the idea
that reducing mTOR signaling in AD may be a valid therapeutic approach.
The level of mTOR signaling that can benefit or harm the condition of PD has also not
been defined. It has been suggested that the inhibition of mTOR activity may be detrimental in
PD [38]. Studies have shown that the expression of REDD1 is increased in Parkinson’s brains
(animal models), leading to the death of dopaminergic neurons [38]. Along with this, if the
downstream effector, 4E-BP1 is activated by leucine-rich repeat kinase 2 (LRRK2), it can alter
protein translation resulting in the loss of dopaminergic neurons [38, 39]. However there are
studies that show mTOR inactivation may preserve dopaminergic neurons. Animal models using
rapamycin as a possible therapeutic approach show that the signaling pathway of AKT maybe
providing neuronal protection [40]. A decrease was observed in the loss of dopaminergic neurons
due to the inhibition of mTOR signaling as a result of autophagy pathway activation [38, 41].
Animal models using rapamycin as a possible therapeutic approach show that the signaling
pathway of AKT maybe providing neuronal protection. It was believed that the inhibition of
mTOR signaling was a result of autophagy pathway activation [41].
In HD, it has been found that the inhibition of mTOR pathway via autophagy promoting
factors may be a possible treatment. Autophagy is responsible for clearing intracellular
huntingtin protein aggregates that can lead to neuronal degeneration therefore considered
important [42]. In fly and murine models, it has been found that rapamycin inhibits mTOR
activity by increasing the autophagic clearance of proteins with long polyglutamine or
polyalanine expansions, thereby attenuating huntingtin accumulation and cell death in HD [42,
43]. However in some experimental models of HD, the inhibition of both mTOR complexes may
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be needed to affect autophagy and the accumulation of huntingtin aggregates [42]. Studies show
that a decrease in activity of p70S6K can protect against early decline in motor skills without
having an effect on huntingtin protein levels [42]. Another study observed that the DNA damage
protein 34 (GADD34) may be required for mTOR to provide neuroprotection in HD. GADD34
function leads to dephosphorylation of TSC2 and induction of autophagy, thereby increasing cell
survival when it is overexpressed [42].
The failure to induce autophagy or the over-enhancement of the pathway can be an
underlying aspect of certain brain pathologies [44]. Autophagy-related genes (ATGs) are key
regulators of the autophagy process; mTOR acts as a regulator by suppressing the autophagy
pathway under nutrient-rich conditions [44]. The inhibition of the TSC1/TSC2 as a result of the
effects of growth factors and nutrient deprivation on the mTOR pathway causes activation of the
mTORC1 complex, thereby inhibiting autophagy [44]. The first studies linking autophagy to the
CNS were performed in animals in which essential regulatory genes (ATG5 and ATG7) were
genetically inactivated [44]. It was found that inactivation of these regulatory genes resulted in
spontaneous neurodegeneration, spontaneous accumulation of protein aggregates, neuronal loss
and premature death [44].

An experimental study tested a Beclin 1(+/-) known-down crossed

into an AD mouse model, to find that Aβ accumulation was promoted, suggesting that autophagy
of Aβ aggregates may be inhibited in AD [45]. Another experiment, using two AD mouse
models treated with rapamycin for 10-13 weeks was conducted to determine the role of
autophagy in AD; rapamycin was found to promote autophagy to decrease Aβ accumulation [45,
46, 47]. These conflicting studies suggests there is a discrepancy in autophagy activity in the AD
brain, therefore further studies must be conducted to elucidate this mechanism.
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CHAPTER 2: SPECIFIC AIMS
The mTOR signaling pathway responds to several environmental cues and integrates
these signals to regulate cell function, homeostasis and proliferation. The mTOR signaling
pathway can impact multiple neurodegenerative diseases including Alzheimer’s, Parkinson’s and
Huntington’s disease. mTOR signaling can affect the early development of cells through stem
cell proliferation and differentiation as well as the end stages of cellular function leading to
autophagy and apoptosis. It is important to understand and elucidate the mechanism by which
folate deficiency has an effect on the mTOR signaling network in brain development and
cognitive decline. It becomes crucial to understand how folate deficiency causes the pathway to
become deregulated or over-enhanced to negatively impact brain development, cognition and
memory. We hypothesize that dietary folate restriction alters the mTOR signaling network in the
brain to provide protection against the onset and progression of neurodegenerative diseases.
Specific Aim 1:
To investigate if folate deficiency provides a protective role against factors contributing to
neurodegenerative diseases in mice.
Specific Aim 2:
To examine the impact of folate deficiency within the mTOR signaling pathway to elucidate the
signaling mechanisms of the substrates.
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CHAPTER 3: METHODS
Animals
The experiments were performed in young adult (6 month), wild-type male C57BL/6
specific pathogen-free mice in accordance with NIH guidelines for the use and care of laboratory
animals. The Wayne State University Animal Investigation Committee approved the animal
protocol. The mice were maintained on a 12-hr light/dark cycle and fed standard mouse chow
and water ad libitum. At 12 weeks of age, the mice were randomly assigned to two dietary
groups and were fed AIN93G-purified isoenergetic diets (Dyets, Inc., Lehigh Valley, PA). Diets
were stored at –20°C. 1% succinyl sulfathiazole was added to all diets. The control group
received a folate adequate diet containing 2 mg/kg folic acid. The experimental group received a
folate-deficient diet containing 0 mg/kg folic acid. The animals' food intake and body weights
were monitored twice weekly to monitor for signs of toxicity and the experimental diets were
continued for 8 weeks. At 24 weeks, mice were anesthetized in a CO2 chamber and sacrificed by
cervical dislocation. Harvested brain was flash frozen and stored in liquid nitrogen [4].
Whole Cell Extraction
Whole cell extraction was performed per standard protocol. 100 mg of brain tissue
samples were extracted using a homogenizer. During the homogenizing process various,
detergents were used: Igepal, Sodium deoxycholate, SDS, PBS, mainly to lyse the cells, denature
some of the protein structures (but not fully damage the proteins), and to place a negative charge
on the protein for it to be linearized. RIPA buffers were added to the brain tissue, it was
homogenized, and thereafter the proteases were added to ensure protein solubility to inhibit any
damages that may have been caused by the denaturing agents. Various spins were conducted as
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protocol demands, to separate pellet from supernatant. The supernatant was the collected very
carefully in a separate tube and put into -80ºC until ready to be used.
Western Blot Analysis
Western blot analysis was performed using 200 µg of crude nuclear extract isolated form
brain tissue per standard protocol. To ensure the correct amount of protein concentration was
used from each sample, the Bradford Assay was performed according to standard protocol and
amounts were determined through normalization. Samples were then subjected to
polyacrylamide gel electrophoresis (SDS-PAGE). Upon completion of SDS-PAGE, the region
containing the protein(s) of interest was excised and prepared for western blot analysis while the
remaining portion of the gel was stained with GelCode®Blue Stain Reagent (Pierce
Biotechnology, Rockford, IL) to ensure equal protein loading. . Western blot analysis was
conducted by using affinity purified polyclonal antisera developed against mouse target proteins.
As an internal control for protein loading, membranes were reprobed with anti-Lamin B antibody
(Santa Cruz Biotechnology, santa Cruz, CA). The bands were visualized and quantified using a
ChemiImager® System (Bio-Rad, Hercules, CA) after incubation in SuperSignal® West Pico
Chemiluminescent Substrate (Pierce Biotechnology, Rockford, IL). Data are expressed as the
integrated density value (I.D.V.) of the band per µg of protein loaded [4].
Statistical Analysis
Statistical significance was determined using an “unpaired t-test”. P values less than 0.05
were considered statistically significant.
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CHAPTER 4: FIGURES
Figure 4-1: Experimental Design

Figure 4-1Experimental Design: The control mice were given a folate adequate diet (2mg/kg
body weight) and the experimental mice were given folate deficient diet (0mg/kg body weight).
The animals' food intake and body weights were monitored twice weekly to monitor for signs of
toxicity and the experimental diets were continued for 8 weeks. Mice were then sacrificed for
analysis at 24 weeks.
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Figure 4-2: Effect of folate adequate vs. folate restricted diet on protein levels of β-actin in
C57BL/6 mice

Figure 4.2 Effect of folate adequate vs. folate restricted diet on protein levels of β-actin in
C57BL/6 mice: In the above figure, an analysis of β-actin protein levels in brain of young
wildtype mice is shown. Experimental mice were given folate deficient diets as described
previously while control mice were given a folate adequate diet. The protein levels were
quantified using Western Blot analysis. Values represent an average (standard error of the mean)
of data obtained from 4 mice of control group and 4 mice of experimental group. Values with an
asterisk superscript indicates significant difference (p<0.05). Levels of β-actin were found to be
statistically insignificant between control and experimental groups. T-test = 0.260963
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Figure 4-3: Effect of folate adequate vs. folate restricted diet on protein levels of Beclin in
C57BL/6 mice

Figure 4.3 Effect of folate adequate vs. folate restricted diet on protein levels of Beclin in
C57BL/6 mice: In the above figure, an analysis of Beclin protein levels in brain of young
wildtype mice is shown. Experimental mice were given folate deficient diets as described
previously while control mice were given a folate adequate diet. The protein levels were
quantified using Western Blot analysis. Values represent an average (standard error of the mean)
of data obtained from 4 mice of control group and 4 mice of experimental group. Values with an
asterisk superscript indicates significant difference (p<0.05). Levels of Beclin show significant
difference comparing control vs. experimental diets. T-test = 0.025006
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Figure 4-4: Effect of folate adequate vs. folate restricted diet on protein levels of ATG7 in
C57BL/6 mice

Figure 4.4 Effect of folate adequate vs. folate restricted diet on protein levels of ATG7 in mice:
In the above figure, an analysis of ATG7 protein levels in brain of young wildtype mice is
shown. Experimental mice were given folate deficient diets as described previously while control
mice were given a folate adequate diet. The protein levels were quantified using Western Blot
analysis. Values represent an average (standard error of the mean) of data obtained from 4 mice
of control group and 4 mice of experimental group. Values with an asterisk superscript indicates
significant difference (p<0.05). Levels of ATG7 show no significant difference comparing
control vs. experimental diets.T-test = 0.471038
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Figure 4-5: Effect of folate adequate vs. folate restricted diet on protein levels of LC3 in
C57BL/6 mice.

Figure 4.5 Effect of folate adequate vs. folate restricted diet on protein levels of LC3 in
C57BL/6 mice: In the above figure, an analysis of LC3 protein levels in brain of young wildtype
mice is shown. Experimental mice were given folate deficient diets as described previously while
control mice were given a folate adequate diet. The protein levels were quantified using Western
Blot analysis. Values represent an average (standard error of the mean) of data obtained from 4
mice of control group and 4 mice of experimental group. Values with an asterisk superscript
indicates significant difference (p<0.05). Levels of LC3 show significant difference comparing
control vs. experimental diets. T-test = 0.00054
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Figure 4-6: Effect of folate adequate vs. folate restricted diet on protein levels of IPMK in
C57BL/6 mice

Figure 4.6 Effect of folate adequate vs. folate restricted diet on protein levels of IPMK in
C57BL/6 mice: In the above figure, an analysis of IPMK protein levels in brain of young
wildtype mice is shown. Experimental mice were given folate deficient diets as described
previously while control mice were given a folate adequate diet. The protein levels were
quantified using Western Blot analysis. Values represent an average (standard error of the mean)
of data obtained from 4 mice of control group and 4 mice of experimental group. Values with an
asterisk superscript indicates significant difference (p<0.05). Levels of IPMK show significant
difference comparing control vs. experimental diets.
T-test = 0.005604002
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Figure 4-7: Effect of folate adequate vs. folate restricted diet on protein levels of REDD-1 in
C57BL/6 mice

Figure 4.7 Effect of folate adequate vs. folate restricted diet on protein levels of REDD-1 in
C57BL/6 mice: In the above figure, an analysis of REDD-1 protein levels in brain of young
wildtype mice is shown. Experimental mice were given folate deficient diets as described
previously while control mice were given a folate adequate diet. The protein levels were
quantified using Western Blot analysis. Values represent an average (standard error of the mean)
of data obtained from 4 mice of control group and 4 mice of experimental group. Values with an
asterisk superscript indicates significant difference (p<0.05). Levels of REDD-1 show significant
difference comparing control vs. experimental diets.
T-test = 0.002287696
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Figure 4-8: Effect of folate adequate vs. folate restricted diet on protein levels of p-AMPK in
C57BL/6 mice

Figure 4.8 Effect of folate adequate vs. folate restricted diet on protein levels of p-AMPK in
C57BL/6 mice: In the above figure, an analysis of p-AMPK protein levels in brain of young
wildtype mice is shown. Experimental mice were given folate deficient diets as described
previously while control mice were given a folate adequate diet. The protein levels were
quantified using Western Blot analysis. Values represent an average (standard error of the mean)
of data obtained from 4 mice of control group and 4 mice of experimental group. Values with an
asterisk superscript indicates significant difference (p<0.05). Levels of p-AMPK show
significant difference comparing control vs. experimental diets.
T-test= 0.000874041
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Figure 4-9: Effect of folate adequate diet vs. folate restricted on protein levels of p-AKT in C57BL/6
mice

Figure 4.9 Effect of folate adequate diet vs. folate restricted on protein levels of p-AKT in
C57BL/6 mice: In the above figure, an analysis of p-AKT protein levels in brain of young
wildtype mice is shown. Experimental mice were given folate deficient diets as described
previously while control mice were given a folate adequate diet. The protein levels were
quantified using Western Blot analysis. Values represent an average (standard error of the mean)
of data obtained from 4 mice of control group and 4 mice of experimental group. Values with an
asterisk superscript indicates significant difference (p<0.05). Levels of p-AKT show significant
difference comparing control vs. experimental diets. T-test= 0.007345.
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Figure 4-10: Effect of folate adequate vs. folate restricted diet on protein levels of p-S6K in
C57BL/6 mice

Figure 4.10 Effect of folate adequate vs. folate restricted diet on protein levels of p-S6K in
C57BL/6 mice: In the above figure, an analysis of p-S6K protein levels in brain of young
wildtype mice is shown. Experimental mice were given folate deficient diets as described
previously while control mice were given a folate adequate diet. The protein levels were
quantified using Western Blot analysis. Values represent an average (standard error of the mean)
of data obtained from 4 mice of control group and 4 mice of experimental group. Values with an
asterisk superscript indicates significant difference (p<0.05). Levels of p-S6K show significant
difference comparing control vs. experimental diets. T-test= 0.001465474.
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CHAPTER 5: RESULTS
Folate deficiency has been associated with neurodegenerative conditions in the elderly;
previous studies have not focused on the effect folate deficiency has on young adult mice. There
have been studies that have observed the influence of rapamycin and the mTOR pathway in the
pathologies of neurodegenerative diseases. The mTOR pathway is stimulated by various
environmental cues and regulates cell processes based on these external cues. It is important to
understand and elucidate the mechanism by which folate deficiency causes the mTOR pathway
to become activated or inhibited to attenuate the onset or progression of pathologies
characteristic of neurodegenerative diseases. An experimental design was prepared in our
laboratory to investigate if folate deficiency provides a protective role against factors
contributing to neurodegenerative diseases via the mTOR pathway. An experimental folate diet
prepared by Harrison et al., was used by our laboratory to conduct this study. This diet was tested
in adult C57/BL6 mice; the mice were separated in two groups: one control and one
experimental group at 3-4 weeks of age. Each group was fed its respective diet ad libitum for 8
weeks and then sacrificed for analysis (Figure 4-1) as described in the materials and methods
section. The samples were obtained from each animal by performing whole cell extraction as
described in the materials and methods section.
To investigate the effect of the diet in the brain of these mice, a western blot protein
analysis (as described in the methods section) was conducted. Figure 4-2 represents a trial
conducted for the control protein, β-Actin, as expected consistent protein expression is observed
in each sample. Autophagy plays a key role in the pathology and progression of Alzheimer’s,
Parkinson’s and Huntington’s disease. Autophagy is a catabolic process used by cells to clear
any damaged proteins and organelles to survive in changing environments. The next thee figures
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focus on autophagy factors of the mTOR pathway. Figure 4-3 displays the effect of folate
deficiency on the protein Beclin1, a significant difference is observed between both control
groups. Beclin1 plays a central role in autophagy and is also required for ATG5/ATG7
dependent and independent autophagy [48]. A higher level of signaling is observed in the FD
mice, therefore autophagy is being promoted. The observed expression of Beclin 1 suggests that
autophagy is not being inhibited, hence possibly providing protection against the accumulation
of Aβ and huntingtin protein aggregates in Alzheimer’s and Huntington’s respectively. In Figure
4-4, the levels of ATG7 do not show a significant difference, however it can be observed that the
FD mice have higher signaling outputs then the FA mice. ATG7 is an E1-like activating enzyme
which activates ATG12 for its conjugation with ATG5 and ATG8. ATG7 is required for
mitophagy which contributes to regulate mitochondrial quantity and quality by eliminating the
mitochondria to a basal level to fulfill cellular energy requirements and prevent the excess
production of ROS (reactive oxygen species) [49]. It modulates the activity of p53/TP53 to
regulate cell cycle and survival during metabolic stress. ATG7 also plays a key role in the
maintenance of axonal homeostasis and the prevention of axonal degeneration [49]. This finding
suggests that the animals are responding to the FD diet and perhaps compensating to survive by
attempting to inhibit mTOR activity at some level. If the animals were on the diet for a longer
period of time, we may be able to see a more significant difference between FA and FD animals.
LC3 is used as another autophagy marker due to its ability to be involved with inner and outer
membrane of the autophagosome. LC3 is synthesized as pro-LC3, which is the processed by
ATG4 into its cytosolic form, LC3-I. During autophagosome formation, ATG3 and ATG7
mediate the covalent linkage of LC3-I to phosphatidylethanolamine (PE), for it to be
incorporated into autophagosome membranes. This process converts LC3-I into LC3-II
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indicating autophagy activity [50]. Figure 4-5 displays the expression of protein levels of LC3, a
significant difference is observed between both animal groups. However in western blot analysis
two bands of the LC3 protein must be detected two signify cleavage and this was not observed.
LC3-I is covalently linking to phosphatidylethanolamine (PE) to be converted into LC3-II
because there is an indication of autophagy occurrence however the level of conversion may be
very low. This may also explain the insignificant expression levels of ATG7 observed in these
animals. Nonetheless, the findings as related to autophagy factors suggest that there are
protective measures being observed against neurodegeneration.
IPMK has been classified as a physiologic mTOR cofactor and it regulates nutrient amino
acid signaling to mTORC1 [33]. IPMK mediates direct binding with mTOR through its unique
amino terminus domain; it senses the level of amino acids present in the cell and activates mTOR
[51]. Figure 4-6 indicates that there is a significant difference in the expression of IPMK levels,
the FD group exhibits much higher expression indicating mTOR activation. An accumulation of
amino acids may be inducing this increased expression of IPMK. REDD-I is an upstream
repressor of mTORC1 and is induced by stress, hypoxia, serum and nutrient deprivation. In
Figure 4-7 the levels of expression of the REDD-I protein are higher in the control group than
that of the experimental group. Lower expression of REDD-I in the experimental group suggests
that the folate deficient diet is not creating a hypoxic environment; perhaps mTOR activity is not
de-regulated. In Parkinson’s brains the increased expression of REDD-I has been proven to be
detrimental as it leads to the death of dopaminergic neurons, therefore this finding suggests that
the FD diet may be acting as a protective measure in PD. AMPK is a protein kinase which senses
intracellular energy and becomes activated as a response to low nutrient availability and ATP
depletion.

AMPK is an important regulator of protein synthesis and energy (lipid and
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carbohydrate) metabolism. The activation of AMPK inhibits the mTORC1 cascade by interacting
with raptor and activating TSC proteins to inhibit Rheb; consequently decreasing the level of
mTORC1. Figure 4-8 displays lower p-AMPK levels in the experimental group. Indicating that
AMP: ATP energy levels are sufficient, therefore potentially resulting in activation of the mTOR
pathway. This finding correlates with the levels of protein of p-AKT and p-S6K expression
observed in the FD diet animals.
mTORC1 is activated by the PI3K/AKT pathway; under normal conditions AKT is
responsible for cell proliferation and endurance. Figure 4-9 exhibits higher levels of p-AKT
expression in the FD animals. AKT s473 phosphorylation is mTORC2 dependent. This implies
that folate deficiency appears to increase mTORC2 activity as a compensatory mechanism to
maintain insulin sensitivity and increase survival. The protein, p70S6K acts directly upon the
mTORC1 complex and is responsible for increasing protein synthesis and cellular proliferation.
mTOR and p70S6K pathways are important in the CNS as amino acids control cortical function
through these pathways. Glutamate and leucine depend upon p70S6K to modulate synaptic
signaling and food intake [36].Figure 4-10 displays the effect of the folate deficient diet on the
protein S6K-1, a significant difference is observed in which the FD group exhibits higher
expression levels of S6K-1, thereby rendering mTORC1 active. Some studies have proven that
hyperactive signaling of mTOR can have detrimental effects in AD patients, nonetheless there
have been studies which have proven that complete mTOR inhibition can be harmful too.
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CHAPTER 6: DISCUSSION
Folate deficiency has been studied extensively due to its association with chronic
diseases, such as Alzheimer’s disease, cancer and cardiovascular disease. In this study we focus
on the effect folate deficiency has on the onset and progression of neurodegenerative diseases in
relation to the mTOR pathway. In response to the FD diet we observed up-regulation of
autophagy, however increased expression of p-S6K and p-AKT contrary to decreased REDD-I
and increased IPMK expression suggested mTOR activation. Higher autophagy occurrence was
indicated by increased expression of Beclin and LC3. Interestingly enough, even though IPMK
levels suggested mTOR inhibition, another upstream effector p-AMPK suggested mTOR
activation.
REDD-I, IPMK and AMPK are upstream effectors of the mTOR pathway. REDD-I is
elevated during hypoxic conditions and nutrient deprivation, however the results indicate that
folate deficiency is not creating a hypoxic environment therefore mTOR may not be effected by
the expression of REDD-I. In Parkinson’s brains the increased expression of REDD-I has been
proven to be detrimental as it leads to the death of dopaminergic neurons, therefore this finding
suggests that the FD diet may be acting as a protective measure in PD. IPMK expression is
found to be elevated in the folate deficient mice, suggesting that mTOR activity is actually
inhibited. One proposal for this behavior is that folate deficiency may be preventing protein
synthesis by inhibiting mTORC1, which could subsequently lead to a buildup of amino acids.
Leading to the over-expression of IPMK without stimulating mTORC1. Previous studies
conducted in our laboratory with folate deficient mice have exhibited lower levels of amino acid
and ATP. Phosphorylated AMPK acts as an energy sensor in the cell, inhibiting mTOR when
energy is low. In nutrient deprivation conditions like folate deficiency, energy depletion is
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expected and is expressed via p-AMPK levels. However in this study the expression of p-AMPK
is interestingly found to be lower in the FD mice, indicating that ATP levels are sufficient,
rendering mTORC1 active. The lower expression of p-AMPK observed in the folate deficient
mice is an unexpected finding; perhaps since IPMK levels are higher there is a buildup of amino
acids triggering sufficient ATP levels.
The expression of Beclin, ATG7 and LC3 is higher in the folate deficient group,
indicating higher levels of autophagy. The failure to induce autophagy has been associated with
brain pathologies, hence the up-regulation of autophagy exerted by the folate deficient diet may
be acting as a protective measure. The levels of Beclin and LC3 were found to be significant,
however LC3 expression did not provide the two bands for analysis, suggesting slow conversion
of LC3-I to LC3-II , thus autophagy is occurring but at a slow rate. Even though ATG7 levels
were not found to be significant the observed results still show that the levels are higher in the
folate deficient mice. This expression may be related to the lower conversion rate of LC3-I to
LC3-II. Autophagy causes the inhibition of the mTOR pathway, however the expression levels
observed in p-S6K and p-AKT suggests that mTOR activation is occurring. p-S6K and p-AKT
are both downstream effectors of the mTOR pathway. p-S6K is responsible for protein synthesis,
cell proliferation and it increases the activity of glycogen synthase kinase, which increases
glucose concentrations. We expected to observe a decrease in p-S6K levels due to the higher
levels of autophagy observed. Possibly the lower level of REDD-I expression is relaying a
message within the cell for S6K to not be phosphorylated since it is not in a hypoxic condition.
This increase in p-S6K activity may be influencing p-AKT activity to be increased due to higher
levels of glucose concentrations being sensed by the cell. Growth factors activate mTORC1
indirectly

by suppressing

TSC1/2

function

through

phosphorylation

of

TSC2

by
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PI3K/AKT/mTOR pathway.

In the FD animals, p-AKT may somehow be prevailing the

signaling of REDD-I and IPMK to the TSC1/2 complex for mTOR activity to be inhibited via
phosphorylation of TSC2.
Our experiments indicate that there has been modulation of the mTOR pathway in the
brain of young adult mice fed a folate deficient mice. The observed results indicate that there
may be an increase in autophagy that occurs in neuronal cells of mice treated with a folate
deficient diet. On the contrary, a folate deficient diet seems to increase the flux of the mTOR
pathway. The confounding results of this study suggests that more research must be done to
fully understand this relationship. Perhaps a study conducted with the animals on the diet for a
longer period of time may provide further insight into these findings.
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ABSTRACT
EFFECT OF FOLATE DEFICIENCY ON EXPRESSION OF PROTEINS ON THE
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Nutrient-gene interactions can significantly impact several cellular processes in the
human body by altering important molecular pathways. Nutrition can affect brain structure,
function and development throughout the life cycle; it can have a profound effect on cognition ad
mental health leading to neurodegenerative diseases. It is important to elucidate the mechanisms
by which diet can effect signaling pathways in the brain. The alteration of the mTOR pathway
has been implicated to be involved in the pathophysiology of neurodegenerative diseases. Due to
the established role of folate playing a role in modulating the mTOR pathway, we decided to
investigate how folate deficiency alters mTOR signaling in the brain. We hypothesized that
dietary folate restriction alters the mTOR signaling network in the brain to provide protection
against the onset and progression of neurodegenerative diseases. In response to the FD diet we
observed higher autophagy occurrence however increased expression of p-S6K and p-AKT
contrary to decreased REDD-I and increased IPMK expression suggested mTOR activation.
Higher autophagy occurrence was indicated by increased expression of Beclin and LC3.
Interestingly enough, even though IPMK levels suggested mTOR inhibition, another upstream
effector p-AMPK suggested mTOR activation.
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